Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Hope Rugo, MD, FASCO, UCSF Comprehensive Cancer Center, San Diego, CA, discusses the SOLAR-1 trial (NCT02437318). This trial is investigating alpelisib with fulvestrant for the treatment of HR+/HER2- advanced breast cancer. Here, Dr Rugo discusses the management and time course of key adverse events of special interest.